



Let's Talk

TB:

A Supplement to GP
CLINICS

Adverse Drug events With Anti Tuberculosis Therapy What Every GP Should Know

Authors: Kavitha Saravu, MD, DNB, DTM&H; Madhukar Pai,
MD, PhD

Standards of TB Care in India

- Pulmonary TB patients treatment:
 - Intensive Phase, First Line: Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA) and Ethambutol (EMB)
 - First 2 months
 - Continuation Phase: INH, RIF and EMB
 - Next 4 months

Standards of TB Care in India

- Course of treatment can be complicated by occurrence of adverse events necessitating treatment interruptions and modified regimens
- Lack of adherence to drugs and treatment interruptions are the driving factors for emergence of drug resistance during the treatment

Adverse drug events (ADE) during anti-tuberculosis therapy (ATT)

- 7% of all drug related adverse events
- 30% of fulminant hepatitis

First Line ATT

- **This review is limited to the common adverse drug events on first line ATT**
 - Extensively used by general practitioners
- Patients requiring second line drugs are best managed by pulmonary or infectious diseases physicians
 - Adverse events during second-line therapy are not discussed in this review

Common Adverse Events (First Line ATT)

TABLE 1. COMMON ADVERSE EVENTS WITH FIRST LINE ATT DRUGS

Drug	Common adverse events
Isoniazid (INH)	Asymptomatic transient elevation of transaminases (20%), hepatitis, peripheral neuropathy, fever, skin rash, seizures, psychosis
Rifampicin (RIF)	Reddish orange color of urine and tears, Pruritus, GI intolerance, Isolated hyperbilirubinemia, hepatitis, pancytopenia, flu like syndrome, acute kidney injury
Pyrazinamide (PZA)	Nausea, vomiting, hepatitis, arthralgia, hyperuricemia, skin rash
Ethambutol (EMB)	Optic neuritis (1-5%), peripheral neuropathy, skin rash
Streptomycin (SM)	Ototoxicity, nephrotoxicity, skin rash

Drug Induced Liver Injury

- Drug induced liver injury is the most severe of the ADE
 - Occurrence of ATT induced hepatitis is estimated to be 5-33%
 - Depending on the definitions used to diagnose hepatitis
 - Most widely used definition of drug induced hepatitis is serum aminotransferase level
 - >5 times the upper limit of normal [ULN] without symptoms
- OR
- >3 times the ULN with symptoms of hepatotoxicity (nausea, vomiting, or pain abdomen)

Drug Induced Liver Injury

- ATT may be associated with asymptomatic elevation of transaminases in about 20% of patients
- It may also result in acute hepatitis, even sub-acute to fulminant hepatitis
 - May be fatal
- The frequency of hepatitis
 - With rifampicin is 0.6-2.7%
 - With Isoniazid is 0.6%

First Line ATT Drugs

- PZA is the most hepatotoxic
 - 15% of patients experiencing hepatic adverse events when higher dose of PZA is used
- The risk of hepatitis is more with combination of INH with RIF or PZA

Types of Hepatotoxicity and Clinical Features

- **Hepatic adaptation**
- **Drug induced acute hepatitis**
- **Granulomatous hepatitis**
- **Cholestasis**

Hepatic adaptation

- Transient asymptomatic elevation of alanine aminotransferase (ALT) may be seen as a physiological response to drug exposure (Cytochrome P450 enzyme induction)

Drug induced acute hepatitis

- Associated with hepatocyte necrosis and elevation of hepatic transaminases with or without jaundice
- Patients may be asymptomatic or may present with nausea, vomiting, abdominal pain and jaundice
- Occasionally they may report constitutional symptoms including fever
- INH and Rifampicin can produce hepatotoxicity by this mechanism

Granulomatous hepatitis

- e.g. Pyrazinamide can produce this and it is a hypersensitivity reaction to the inciting drug with granuloma formation
- Patients may present with fever, lethargy, body ache, rash, lymphadenopathy and hepatosplenomegaly
- Biochemical examination will reveal elevation of serum transaminases along with alkaline phosphatase

Cholestasis

- Usually associated with asymptomatic elevation of alkaline phosphatase along with bilirubin because of failure of bilirubin transport
 - e.g. seen with rifampicin

Risk Factors for Hepatotoxicity

- Age >35 years
- Children
- Female gender
- Recent child birth (<3 months post-partum)
- Alcohol abuse
- Abnormal baseline liver enzymes
- Slow acetylator status- associated with INH associated hepatotoxicity
- Malnutrition/hypoalbuminemia

Recognition of Drug Induced Hepatitis

Recognition of Drug Induced Hepatitis

- It is important for doctors to suspect drug induced liver injury when patients on ATT present with nausea, vomiting, right hypochondriac pain, and jaundice
- Temporal pattern of disease evolution after exposure to drugs is important to diagnose drug induced adverse events

Recognition of Drug Induced Hepatitis

- Liver function tests must be requested on suspecting liver injury
 - Drug induced hepatitis is diagnosed when serum amino- transferase level >5 times the ULN without symptoms or >3 times the ULN with symptoms

Recognition of Drug Induced Hepatitis

- Bilirubin may or may not be elevated
- Early detection of drug induced liver disease is critical to prevent severe or chronic liver disease
- Patients should be advised to report any untoward symptoms:
 - nausea, malaise, lethargy, right hypochondriac pain or new onset fever

Management of Patients with Drug Induced Hepatotoxicity

Management of Patients with Drug Induced Hepatotoxicity

- Once hepatotoxicity is suspected, all hepatotoxic drugs must be stopped and promptly investigated as mentioned
 - Failure to discontinue a drug that is causing liver injury leads to poor outcome such as acute liver failure or chronic hepatitis

Management of Patients with Drug Induced Hepatotoxicity

- The specific risk factors for drug induced hepatotoxicity have to be carefully elicited
- In all patients with liver abnormality, history of hazardous intake of alcohol, other hepatotoxic drug ingestion must be enquired about and viral hepatitis must be ruled out

Management of Patients with Drug Induced Hepatotoxicity

- No hepatoprotective agent has been effective in ameliorating drug induced liver damage
- Non hepatotoxic ATT drugs which could be used are streptomycin, ethambutol and levofloxacin or moxifloxacin

Management of Patients with Drug Induced Hepatotoxicity

- Patient should be observed for progress and the liver function tests [LFT] should be monitored once in 3 days
- Usually symptoms and laboratory abnormalities promptly improve within days or weeks once the inciting drugs are stopped

Management of Patients with Drug Induced Hepatotoxicity

- When the ALT returns to less than 2 times the ULN, gradually drugs are reintroduced sequentially with rifampicin, INH and PZA in that order with a gap of 3-7 days between each drug and monitoring of LFT
 - If symptoms recur or ALT increases, the last drug added should be stopped

Management of Patients with Drug Induced Hepatotoxicity

- In those patients who had experienced severe or prolonged hepatotoxicity, reintroduction of PZA may be avoided and the duration of ATT may be extended to 9 months

Gastrointestinal Adverse Effects

Gastrointestinal Adverse Effects

- GI adverse events are usually minor
- Nausea, vomiting and abdominal discomfort, which may be self-limiting
- This may be due to mild gastritis and can be managed by the addition of proton pump inhibitors, anti-emetics, administering drugs after meals or by giving drugs at an interval

Gastrointestinal Adverse Effects

- Discontinuation of ATT is usually not required
- In all such patients with the above mentioned symptoms, LFT must be requested to rule out early liver toxicity

Dermatological Adverse Effects

Dermatological Adverse Effects

- Skin related ADE can occur with all anti TB drugs and is one of the common side effects in up to 6% of patients on ATT
- It can be in varying forms like maculopapular rash, erythema multiforme syndrome, acneiform eruptions, urticarial, lichenoid eruptions, the more severe exfoliative dermatitis and Steven Johnson Syndrome
- Exfoliative dermatitis also called erythroderma, a form of cutaneous hypersensitivity occurs after 6-8 weeks of therapy

Dermatological Adverse Effects

- The propensity of the drugs to cause erythroderma is PZA >SM >EMB >RIF >INH with rates for PZA being 2.4%
- Steven Johnson syndrome is a life threatening mucocutaneous syndrome and it has been described with RIF, INH, PZA and thiacetazone

Dermatological Adverse Effects

- In patients with itching/ minimal rash, ATT can be continued along with symptomatic treatment with anti-histamines
- If visible maculopapular rash, all the drugs have to be stopped and antihistamines have to be prescribed
 - Re-introduction of the ATT is to be done with INH followed by RIF, EMB and PZA with careful monitoring

Neurological Adverse Effects

Neurological Adverse Effects

- CNS adverse events include seizures, psychosis, ototoxicity, and optic neuritis
- The drug most commonly implicated in psychosis is INH followed by cycloserine
- Seizures are a side effect of INH, fluoroquinolones, and cycloserine

Neurological Adverse Effects

- Ototoxicity and neuromuscular blockade are adverse events of aminoglycosides, while ethambutol is known to cause optic neuritis.
- Ototoxicity and optic neuritis are dose dependent

Neurological Adverse Effects

- It is important to ask patients about tinnitus, imbalance, vertigo or decreased hearing while the patients are on aminoglycosides
- As children may not be able to complain about decreased vision, or impairment of color perception (which is a classical symptoms of optic neuritis), ethambutol is best avoided in children

Neurological Adverse Effects

- Peripheral neuropathy, manifested by tingling and numbness in hands and feet is a side effect of INH (seen in up to 2% of patients)
 - Less commonly ethambutol and ethionamide
- The risk factors for peripheral neuropathy are malnutrition, HIV infection, diabetes mellitus, alcohol abuse and concomitant drugs having neuropathy potential such as Stavudine

Neurological Adverse Effects

- It is best to prevent peripheral neuropathy by pyridoxine supplementation (40mg daily) to all patients with the neuropathy risk factors receiving INH
- The involved drugs have to be stopped promptly on the first suspicion of seizures, psychosis, ototoxicity or visual toxicity and never administered again

Musculoskeletal Adverse Effects

Musculoskeletal Adverse Effects

- Mild arthralgia may be associated with PZA, and is associated with elevated uric acid
 - It can be managed symptomatically with NSAIDS

Renal Adverse Events

Renal Adverse Events

- Acute kidney injury (acute renal failure) with normal urine output can occur with aminoglycosides
- Rarely, rifampicin can give rise to interstitial nephritis

Drug Induced Haematological Adverse Events

Drug Induced Haematological Adverse Events

- Immune mediated cytopenia of all three cell lines, including agranulocytosis have been described with ATT
- Thrombocytopenia is an uncommon but potentially life-threatening complication and is characterized by rapid destruction of platelets in susceptible patients due to immune mechanisms

Drug Induced Haematological Adverse Events

- Patients usually present with purpuric rashes all over the body
 - Reported classically with RIF
 - PZA, EMB and INH are also implicated in various case reports

Drug Induced Haematological Adverse Events

- The diagnosis is by resolution of symptoms and improvement of platelet count on stopping the drugs
- Treatment is by discontinuation of the drugs, transfusion of platelets if platelet count is $<20,000/\mu\text{L}$
- Patient has to be managed with 3 new anti tuberculosis drugs including one parenteral agent

Drug Induced Haematological Adverse Events

- Rifampicin is also implicated with life threatening drug induced hemolytic anemia due to immune mechanisms
- It can manifest with severe anemia requiring blood transfusion and jaundice due to indirect hyperbilirubinemia
- Re-challenge with the offending drug is contraindicated both in drug induced thrombocytopenia and hemolysis as minute quantity of the drug can trigger a very severe reaction

Monitoring of Patients for ADE on ATT

- All patients should undergo baseline testing of serum bilirubin, transaminases, alkaline phosphatase, creatinine, and complete blood count

Monitoring of Patients for ADE on ATT

- **In those with risk factors for hepatotoxicity:** every 2-4 weekly monitoring of liver function tests is recommended
- **In those without risk factors for hepatotoxicity:** routine LFT monitoring is not required unless symptomatic
- During each visit, patients should be asked about symptoms of possible ADE relevant to the regimen they are receiving

CLINICAL HIGHLIGHTS

- The course of treatment of TB can be complicated by drug induced adverse events and GP's knowledge about their occurrences and competency to diagnose them are critical for the successful outcome.
- Minor adverse reactions to TB medications include nausea, gastric intolerance, neuropathy, itching and joint pains that can be managed symptomatically and do not warrant stoppage of medications.
- Major adverse reactions include hepatitis, severe skin reactions, optic neuropathy thrombocytopenia, hemolysis, and renal failure. Symptoms and signs suggesting a major reaction should be treated by stoppage of drugs, and close monitoring.
- Drug induced liver injury is the most common serious adverse event which may present as nausea, vomiting, jaundice, right hypochondriac pain and requires stoppage of all hepatotoxic drugs with monitoring of liver functions and subsequent reintroduction of drugs sequentially.
- Patients with pre-existing liver disease, viral hepatitis, chronic alcohol consumption, pregnant women, or postpartum period, HIV infection and on concomitant hepatotoxic medications are particularly at high risk of ATT induced hepatitis and these risk factors must be carefully sought prior to the initiation of ATT and are to be monitored with LFT every 2-4 weekly on therapy.

- On reintroduction of ATT, it is important to avoid mono therapy to prevent emergence of drug resistant TB. Non hepatotoxic drugs like streptomycin, ethambutol and moxifloxacin can be given, when hepatotoxic drugs need to be stopped.
- Life threatening complications like immune thrombocytopenia, immune hemolytic anemia, Steven Johnson syndrome, and organ threatening complications such as ototoxicity, nephrotoxicity, and ocular toxicity are absolute contraindications to rechallenge with the suspected drug.
- All patients need to be counselled on how to identify ADEs, before initiation of ATT.

References:

1. World Health Organization Country Office for India. Standards for TB Care in India. URL: <http://tbevidence.org/wp-content/uploads/2014/04/STCI-2014.pdf> 2014
2. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jeeb JA, Nolan CM, et al. ATS {American Thoracic Society} hepatotoxicity of antituberculosis therapy subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med*. 2006;11: 699-707.
3. Tostmann A, Boeree MJ, Aarnoutse RE, Lange WC, Van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review *Journal of Gastroenterology and Hepatology*. 2008;23:192-202.
4. Garg PK, Tandon RK. Antituberculosis treatment induced hepatotoxicity. In: Sharma SK, Mohan A, editors. *Tuberculosis. 2nd ed*. New Delhi: Jaypee brothers medical publishers Ltd; 2009. P 783-795.
5. O'Donnell MR, Reddy D, Saukkonen JJ. Antimycobacterial agents. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J et al., editors. *Harrison's principles of internal medicine. 19th ed*. New York: McGraw Hill; 2012. 205e-208e.
6. Dua R, Sindwani G, Rawat J. Exfoliative dermatitis to all four first line anti-tubercular therapy. *Indian J of Tuberculosis*. 2010; 57:53-56.
7. Patel PP, Gandhi AM, Desai CK, Desai MK, Dikshit RK. An analysis of drug induced Stevens Johnson Syndrome. *Indian J Med Res*. 2012; 136: 1051-1053.
8. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. *CNS Drugs*. 2010 Aug; 24(8):655-67.
9. Kant S, Natu NK, Mahajan V. Rifampicin, ethambutol and pyrazinamide induced thrombocytopenia. *Int J Clin Pharmacol Ther*. 2008;46:823-25.
10. Ahrens N, Genth R, Salama A. Belated diagnosis in three patients with rifampicin-induced immune haemolytic anaemia. *Br J Haematol*. 2002;117(2):441-3.